Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences

Group 1 - The high cost of drug development, estimated at $1 billion from preclinical research to commercialization, remains a significant burden in the life sciences industry [1] - Model-Informed Drug Development (MIDD) is identified as a potential solution to reduce drug development costs [1] - The company ELAM1 provides financial professionals and investors with the necessary scientific and clinical expertise to navigate the complexities of the healthcare sector [1] Group 2 - ELAM1 aims to bridge the gap between advanced scientific research and financial strategy, helping clients uncover hidden value and assess risks more accurately [1]